Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.85 EUR | +1.50% | +2.99% | +18.95% |
Mar. 28 | GSK : Sell rating from JP Morgan | ZD |
Mar. 28 | U.S. FDA approves Akebia's anemia drug | RE |
Sales 2024 * | 31.54B 39.84B 36.89B | Sales 2025 * | 33.44B 42.25B 39.12B | Capitalization | 69.81B 88.19B 81.66B |
---|---|---|---|---|---|
Net income 2024 * | 5.6B 7.08B 6.56B | Net income 2025 * | 6.25B 7.9B 7.31B | EV / Sales 2024 * | 2.61 x |
Net Debt 2024 * | 12.51B 15.81B 14.64B | Net Debt 2025 * | 9.38B 11.85B 10.97B | EV / Sales 2025 * | 2.37 x |
P/E ratio 2024 * |
12.5
x | P/E ratio 2025 * |
11
x | Employees | 70,212 |
Yield 2024 * |
3.59% | Yield 2025 * |
3.88% | Free-Float | 92.08% |
Latest transcript on GSK plc
1 day | +1.50% | ||
1 week | +2.99% | ||
Current month | +1.76% | ||
1 month | +2.33% | ||
3 months | +20.35% | ||
6 months | +16.30% | ||
Current year | +18.95% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 19.85 | +1.50% | 890 |
24-03-27 | 19.55 | +0.35% | 477 |
24-03-26 | 19.48 | -0.59% | 1,668 |
24-03-25 | 19.6 | +0.84% | 2,425 |
24-03-22 | 19.44 | +0.86% | 560 |
Delayed Quote Deutsche Boerse AG, March 28, 2024 at 04:50 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+2.95% | 212B | |
+0.74% | 209B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock GSK plc
- Stock GSK plc - Deutsche Boerse AG